查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832514

细胞治疗市场按类型、治疗类型、给药方法、应用和最终用户划分—2025-2032 年全球预测

Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年细胞治疗市场规模将成长至 225 亿美元，复合年增长率为 11.22%。

主要市场统计数据
基准年2024年 96亿美元
预计2025年 106.4亿美元
预测年份：2032年 225亿美元
复合年增长率（%） 11.22%

细胞疗法已成为现代生物医学领域最具活力的前沿领域之一，透过融合先进的细胞工程、免疫学和再生方法，满足尚未满足的临床需求。近年来，科学进展已从概念验证研究转向日益复杂的临床项目，涵盖自体和同种异体构建体、多样化的给药方法以及更广泛的治疗应用。随着技术堆迭的成熟，相关人员如今面临着科学、监管、製造和商业性力量的复杂相互作用，这些力量将决定转化疗法的成功。

本导言透过强调将影响专案进度和商业性准备的策略曲折点，帮助读者置身于这种复杂环境中。本书强调了平台标准化、模组化製造和付款人参与等趋同趋势，这些趋势推动着开发商、服务供应商和临床机构的决策。重要的是，本书的视角超越了实验室，涵盖了现实世界的实施挑战，包括供应链弹性、载体生产和病患获取途径。本章从商业视角审视这一形势，帮助领导者评估投资重点、如何降低风险，以及哪些伙伴关係能够加速从临床前景到永续治疗交付的转变。

由于技术突破、监管演变、製造进步和付款人参与动态，细胞治疗领域正在发生重大变化。

近年来，细胞治疗领域经历了重大变革，这既得益于技术突破，也得益于患者治疗方式的系统性转变。基因编辑和模组化製造方法减少了技术瓶颈，并实现了治疗结构的迭代改进。同时，监管机构也采用了适应性证据框架，改变了研发时间表，并为有条件的市场准入开闢了新的途径。总的来说，这些变化加速了学习週期，并使得从早期临床试验到更广泛的临床计画的过渡更快。

同时，随着支付方和医疗保健提供者日益重视现实世界的结果和长期价值，商业化动态也随之演变。这种转变迫使申办方设计超越随机对照试验的证据策略，涵盖註册库、实用性试验和健康经济模型。製造业也正在经历结构性转变，为了应对物流复杂性和区域准入挑战，分散式和混合式製造模式越来越受到青睐。总体而言，这些转型变革为开发商、製造外包、临床中心和支付方之间的合作创造了新的机会，并要求制定能够平衡科学抱负和营运扩充性的适应性策略。

2025年美国关税变化对细胞治疗供应链的累积影响：跨境采购组件的定价和策略采购考量

美国将于2025年实施关税改革，将对细胞疗法供应链、采购决策和跨国筹资策略产生连锁影响。儘管细胞疗法研发的许多环节依赖全球采购的专用试剂、耗材和设备，但关税已经改变了供应商的相对经济效益，促使专案团队重新评估其供应商组合。因此，筹资策略正转向地域多元化、更深入地评估替代供应商的资格以及规避单一来源的风险。

应对关税成本压力的措施包括重新协商供应商合约、延长关键原材料的库存前置作业时间，以及尽可能加快上游工程的本地化。生产规划人员评估了集中式大批量生产与规模较小、区域化生产基地之间的利弊，这些基地可以降低关税和物流的脆弱性。同时，临床实验试验管理人员也调整了选址标准，以应对潜在的关税延迟和试剂供应问题，从而影响试验计划和患者入组速度。这些累积影响凸显了动态供应链管治、情境规划和积极主动的监管参与的必要性，以便在对外贸易政策发生变化的情况下，保持计画的连续性和临床计画的顺利进行。

关键市场细分洞察揭示了治疗类型、给药途径、临床用途、地理来源和最终用户如何决定开发平臺和市场发展

透过细分市场分析，我们发现不同的发展路径和临床用例​​需要不同的策略方法。非干细胞类别包括CAR-T细胞、树突状细胞和自然杀手细胞项目，每个项目都有各自的生产足迹和临床终点。同时，干细胞类别包括胚胎干细胞、造血干细胞和间质干细胞，每个项目都有不同的伦理、监管和规模化考量。根据治疗方法来源，项目分为同种异体和自体，自体疗法需要个人化的供应链和患者材料物流，而同种异体疗法则强调大量生产和细胞库的持久性。

肌肉注射、肿瘤内注射和静脉注射有不同的临床工作流程、安全监测和製剂稳定性要求。自体免疫疾病（例如多发性硬化症和类风湿性关节炎）需要慢性治疗模式和长期安全监测，而骨髓恶性肿瘤和固态肿瘤的肿瘤学治疗方案也有所不同，具有不同的肿瘤微环境挑战和反应指标。感染疾病的应用涵盖细菌和病毒感染，具有不同的急性治疗时间表和监管终点。最后，最终用户（包括学术和研究机构、诊所、商业实验室和医院）在不同的采购、基础设施和报销环境中运营，这会影响采用速度和核准后支援模式。整合这些细分市场可以使开发策略与临床、营运和商业现实更加准确地保持一致。

美洲、中东和非洲以及亚太地区的区域动态和战略考量影响製造地和临床试验中心的准入

区域动态对专案设计、生产策略和市场进入规划有着强大的影响，美洲、欧洲、中东和非洲以及亚太地区呈现出明显的区域动态。在美洲，卓越的临床中心和强大的投资生态系统推动先进的临床项目和大规模生产倡议，而监管机构则强调安全性和上市后证据。在欧洲、中东和非洲，跨多个司法管辖区的监管协调和强大的临床网络正在塑造跨国临床试验设计和联合生产伙伴关係，但各国的报销框架差异很大，可能会影响上市顺序。

亚太地区拥有多元化的临床和生产能力，多个国家正在成为早期临床开发和受託製造的区域中心。一些市场的监管现代化正在加速本地临床试验的发展。在每个地区，临床基础设施、人才和本地生产奖励相互作用，推动着关于场地位置和临床试验执行的决策。此外，随着相关人员寻求在韧性与成本效益和病患可及性需求之间取得平衡，跨境合作、技术转移协议和区域供应路线也在不断发展。

对细胞治疗生态系统中的主要企业进行审查，重点关注竞争定位、合作模式、平台专业化和竞争差异化策略

细胞疗法生态系统中的主要企业展现出差异化策略，体现了其核心竞争力和长远目标。大型製药企业通常会透过平台收购或策略联盟，将细胞疗法能力整合到其更广泛的免疫肿瘤学或再生医学产品组合中，并利用其商业基础设施来扩大其后期产品线。纯细胞疗法开发者往往专注于科学差异化，例如新颖的工程构建体或独特的细胞表型，优先考虑转化概念验证和临床差异化，以确保获得伙伴关係和许可协议。

製造和技术服务提供者强调可扩展性、品质系统和供应链可靠性，将自己定位为缺乏内部製造能力的公司的必要推动者。工具和试剂供应商正凭藉专有技术、自动化解决方案和检验的耗材来降低製程差异，从而实现差异化。学术衍生公司和研究机构继续发挥创新来源的作用，将基础发现转化为早期临床计画。在所有这些相关人员中，从共同开发伙伴关係到按服务收费安排等各种合作模式正在塑造能力的整合方式。竞争差异化日益取决于可重复製造、满足监管要求以及在核准后产生可靠真实世界证据的能力。

为行业领导者提供切实可行的建议，以加速翻译，优化供应链，加强监管参与，并确保永续的商业性发展道路。

产业领导者应采取一系列切实可行的倡议，在短期实用性与长期策略定位之间取得平衡。首先，透过设计能够同时产生监管和付款人相关终点的试验，将研发重点与可操作证据的生成结合。其次，透过识别二级供应商、制定区域筹资策略以及考虑混合製造布局来投资供应链韧性，以减轻关税和物流脆弱性的影响。

研发领导者还必须优先考虑早期和持续的监管参与，利用科学建议和灵活的监管途径，降低关键研发步骤的风险，并明确核准后证据的前景。他们必须积极寻求策略伙伴关係，与製造外包、临床网路和技术供应商合作，以加速产能扩张，同时保持资本效率。他们还必须将卫生经济学和疗效研究纳入研发计划，以向付款人和医疗保健系统证明其价值。最后，他们必须透过投资自动化、数位身分共同追踪和员工发展项目来促进卓越运营，以减少差异性，并加快自体和异体计画的患者获准时间。

调查方法与证据综合 资料来源描述 专家咨询分析法 用于建构分析的架构与检验过程

调查方法将结构化证据整合与初步质性研究相结合，以提供稳健且检验的分析。此方法首先全面回顾已发表的科学文献、监管指南文件、临床试验註册和专利态势，以深入了解该平台技术及其临床发展轨迹。随后，研究提出了关键的主题假设，并透过专家咨询检验，包括采访临床实验人员、生产主管、研究人员和监管专家，提供营运背景和未来展望。

所采用的分析架构包括：供应链图谱识别瓶颈、細項分析使专案策略与临床用例保持一致，以及情境规划评估政策和贸易影响。研究结果透过证据来源三角最后覆核，并在与领域专家的研讨会上检验，以确保实践相关性并完善建议。在整个过程中，我们强调假设的透明度、证据的可追溯性以及结合相关人员回馈的迭代检验循环，以提高洞察的准确性和适用性。

结论总结，重点强调了相关人员在细胞治疗中最大化临床和商业性影响的策略要务、持续挑战和实际途径

结论简洁地总结了该分析，并将其作为整个细胞治疗生态系统相关人员的策略要务。儘管科学发展势头持续扩大潜在的治疗成分，但商业性成功越来越依赖製造、供应链和付款人参与的卓越营运。将科学差异化与可重复、扩充性的流程以及早期价值展示相结合的组织，将能够更好地满足监管期望并确保持续的市场进入。持续存在的挑战，例如自体治疗物流、製造差异性和区域监管碎片化，需要一种协调一致的应对策略，将公私合作与有针对性的投资相结合。

展望未来，生态系统将奖励那些适应性强的组织，这些组织采用模组化生产模式，投资于用于身分和结果追踪的数位基础设施，并积极与付款方合作，设计反映实际绩效的证据包。将这些策略重点与严格的执行相结合，将使相关人员能够加快患者可及性，同时管理先进细胞疗法固有的营运复杂性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 标准化剂量和缩短製造时间将使现成的同种异体CAR-T 疗法迅速出现
  • 整合自动化封闭回路型生物反应器系统，实现可扩展的生产和品管
  • 应用 CRISPR 基因编辑技术设计出具有增强肿瘤特异性的下一代通用供体 T 细胞
  • 引入分散式 POC 製造，以简化自体细胞疗法向远距治疗中心的交付
  • 引入人工智慧主导的分析，用于即时效力评估和细胞治疗释放标准的优化
  • 透过调节肿瘤微环境的策略将细胞治疗应用扩展到固态肿瘤
  • 开发将细胞疗法与免疫查核点抑制剂结合的联合治疗，以提高持久缓解率
  • 建立全球监管协调框架，加速细胞疗法的临床应用和市场核准

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章细胞治疗市场（按类型）

  • 非干细胞
    • CAR-T细胞
    • 树突状细胞
    • NK细胞
  • 干细胞
    • 胚胎干细胞
    • 造血干细胞
    • 间质干细胞

第九章 细胞治疗市场（依治疗类型）

  • 同种
  • 自体移植

第 10 章 细胞治疗市场（依给药方法）

  • 肌肉注射
  • 肿瘤内
  • 静脉

第 11 章细胞治疗市场：依应用

  • 自体免疫疾病
    • 多发性硬化症
    • 类风湿性关节炎
  • 癌症治疗
    • 造血系统恶性肿瘤
    • 固态肿瘤
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染
  • 再生医学

第 12 章 细胞治疗市场（依最终使用者）

  • 学术研究机构
  • 诊所
  • 商业实验室
  • 医院

第十三章 细胞治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章细胞治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国细胞治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Anterogen Co., Ltd.
    • Astellas Pharma Inc.
    • Athersys, Inc.
    • BioNTech SE
    • Bristol-Myers Squibb Company
    • Castle Creek Biosciences, Inc.
    • Catalent, Inc.
    • FUJIFILM Holdings Corporation
    • Gilead Sciences, Inc.
    • JCR Pharmaceuticals Co., Ltd.
    • Kolon TissueGene, Inc.
    • Lonza Group Ltd.
    • Medipost Co., Ltd.
    • Mesoblast Ltd.
    • Novartis AG
    • NuVasive, Inc.
    • Pfizer Inc.
    • Sartorius AG
    • Stemedica Cell Technologies, Inc.
    • Stempeutics Research Pvt. Ltd.
    • Takeda Pharmaceutical Company Limited
    • TegoScience
    • Thermo Fisher Scientific, Inc.
    • Vericel Corporation
Product Code: MRR-433AB1DC28D4

The Cell Therapy Market is projected to grow by USD 22.50 billion at a CAGR of 11.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.60 billion
Estimated Year [2025] USD 10.64 billion
Forecast Year [2032] USD 22.50 billion
CAGR (%) 11.22%

Cell therapy has emerged as one of the most dynamic frontiers in modern biomedicine, blending advanced cellular engineering, immunology, and regenerative approaches to address unmet clinical needs. Over recent years, scientific progress has migrated from conceptual proof-of-concept work into increasingly sophisticated clinical programs that span autologous and allogenic constructs, diverse modes of administration, and a widening set of therapeutic applications. As the technology stack matures, stakeholders now confront a complex interplay of scientific, regulatory, manufacturing, and commercial forces that shape translational success.

This introduction situates readers within that complexity by focusing on the strategic inflection points that influence program progression and commercial readiness. It emphasizes the convergent trends-platform standardization, modular manufacturing, and payer engagement-that drive decision-making across developers, service providers, and clinical institutions. Importantly, the narrative moves beyond the laboratory to consider real-world implementation challenges, including supply chain resilience, vector production, and patient access pathways. By framing the landscape in operational terms, the section prepares leaders to assess where to concentrate investment, how to mitigate risk, and which partnerships accelerate movement from clinical promise to sustainable therapeutic delivery.

Transformative shifts reshaping the cell therapy landscape driven by technological breakthroughs regulatory evolution manufacturing advances and payer engagement dynamics

Recent years have produced transformative shifts across the cell therapy landscape, driven by both technological breakthroughs and systemic changes in how therapies progress to patients. Gene editing and modular manufacturing approaches have reduced technical bottlenecks and enabled iterative refinement of therapeutic constructs. In parallel, regulatory agencies have signaled greater willingness to engage in adaptive evidence frameworks, which has altered development timelines and opened new pathways for conditional market access. These changes collectively accelerate learning cycles and enable faster translation from early clinical studies into broader clinical programs.

Concurrently, commercialization dynamics have evolved as payers and providers emphasize real-world outcomes and long-term value. This shift compels sponsors to design evidence strategies that extend beyond randomized controlled trials to include registries, pragmatic studies, and health economic models. Manufacturing has also experienced a structural pivot: decentralized and hybrid production models are gaining traction as a response to logistical complexity and regional access challenges. Altogether, these transformative shifts create new opportunities for collaboration between developers, contract manufacturers, clinical centers, and payers, and they demand adaptive strategies that balance scientific ambition with operational scalability.

Cumulative implications of United States tariff changes in 2025 on cell therapy supply chains cross-border sourcing component pricing and strategic procurement considerations

The introduction of tariff changes in the United States in 2025 has exerted a cascading influence on cell therapy supply chains, procurement decisions, and cross-border sourcing strategies. While many components of cell therapy development depend on specialized reagents, disposables, and instrumentation sourced globally, tariffs have altered relative supplier economics and prompted program teams to reassess supplier portfolios. As a result, procurement strategies have shifted toward increased geographic diversification and deeper qualification of alternative suppliers to hedge against single-source exposure.

Operational responses to tariff-induced cost pressures include renegotiating supplier contracts, extending inventory lead times for critical materials, and accelerating localization of upstream activities where feasible. Manufacturing planners have evaluated the trade-off between centralized high-volume production versus regionalized, smaller-scale facilities that reduce tariff and logistics vulnerability. In parallel, clinical trial managers have adapted site selection criteria to factor in potential customs delays and reagent availability, which affects scheduling and patient enrollment pacing. These cumulative effects underscore the need for dynamic supply-chain governance, scenario planning, and proactive regulatory engagement to maintain program continuity and preserve clinical timelines despite external trade policy shifts.

Key segmentation insights revealing how therapeutic type administration route clinical application therapy origin and end users define development pipelines and market access

Deconstructing the market through segmentation reveals how different development pathways and clinical use cases necessitate distinct strategic approaches. When examined by type, the landscape is split between Non-stem Cells and Stem Cells; the Non-stem Cells category prominently includes CAR-T cells, dendritic cells, and natural killer cell programs, each with unique manufacturing footprints and clinical endpoints, while the Stem Cells category comprises embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells, which raise distinct ethical, regulatory, and scale-up considerations. Based on therapy origin, programs cluster into allogenic and autologous modalities, where autologous approaches require personalized supply chains and patient material logistics and allogenic approaches emphasize batch manufacturing and durability of cell banks.

Administration routes further differentiate development and adoption strategies: intramuscular, intratumoral, and intravenous deliveries impose varied clinical workflows, safety monitoring, and formulation stability requirements. Application-driven segmentation highlights pathway-specific needs: autoimmune disorders-such as multiple sclerosis and rheumatoid arthritis-demand chronic treatment models and long-term safety surveillance, whereas cancer treatment programs diverge between hematologic malignancies and solid tumors with corresponding differences in tumor microenvironment challenges and response metrics. Infectious disease applications span bacterial and viral infections with acute treatment timelines and distinct regulatory endpoints. Finally, end users including academic and research institutes, clinics, commercial laboratories, and hospitals each operate within different procurement, infrastructure, and reimbursement environments, which influences adoption speed and post-approval support models. Integrating these segmentation lenses enables more precise alignment of development strategies with clinical, operational, and commercial realities.

Regional dynamics and strategic considerations across Americas Europe Middle East & Africa and Asia-Pacific that influence clinical trial hubs manufacturing sites and access

Regional dynamics exert a powerful influence on program design, manufacturing strategy, and market access planning, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, centers of clinical excellence and a robust investment ecosystem drive advanced clinical programs and large-scale manufacturing initiatives, while regulatory pathways emphasize safety and post-market evidence commitments. In Europe, Middle East & Africa, regulatory harmonization across multiple jurisdictions and strong clinical networks shape multinational trial designs and collaborative manufacturing partnerships, although country-level reimbursement frameworks can vary significantly and influence launch sequencing.

Asia-Pacific presents a diverse range of clinical competencies and manufacturing capabilities, with several countries emerging as regional hubs for both early clinical development and contract manufacturing services; favorable regulatory modernization in some markets has accelerated local trial activity. Across all regions, the interplay between clinical infrastructure, talent availability, and local manufacturing incentives informs decisions on facility placement and trial execution. Moreover, cross-border collaborations, technology transfer agreements, and regional supply routes continue to evolve as stakeholders seek to balance resilience with cost efficiency and patient access imperatives.

Key company insights spotlighting competitive positioning collaboration models platform specialization and competitive differentiation strategies within cell therapy ecosystems

Key companies operating across the cell therapy ecosystem exhibit differentiated strategies that reflect their core capabilities and long-term ambitions. Large pharmaceutical firms often pursue platform acquisition and strategic partnerships to integrate cell therapy capabilities into broader immuno-oncology and regenerative portfolios, leveraging their commercial infrastructure to scale later-stage products. Pure-play cell therapy developers tend to focus on scientific differentiation-such as novel engineering constructs or unique cell phenotypes-and they prioritize translational proof and clinical differentiation to attract partnerships or licensing deals.

Providers of manufacturing and technical services emphasize scalability, quality systems, and supply-chain reliability, positioning themselves as essential enablers for companies that lack in-house production capacity. Tool and reagent suppliers differentiate through proprietary technologies, automation solutions, and validated consumables that reduce process variability. Academic spinouts and research institutes continue to serve as innovation sources, translating basic discoveries into early clinical programs. Across all these actors, collaboration models-ranging from co-development partnerships to fee-for-service arrangements-shape how capabilities are combined. Competitive differentiation increasingly hinges on demonstrated manufacturing reproducibility, regulatory readiness, and the ability to generate robust real-world evidence post-approval.

Actionable recommendations for industry leaders to accelerate translation optimize supply chains enhance regulatory engagement and secure sustainable commercial pathways

Industry leaders should pursue a set of pragmatic, actionable moves that balance near-term operability with long-term strategic positioning. First, align R&D priorities with pragmatic evidence generation by designing trials that produce both regulatory and payer-relevant endpoints; this dual focus accelerates market access discussions and reduces downstream negotiation risk. Next, invest in supply-chain resilience by qualifying secondary suppliers, developing regional sourcing strategies, and examining hybrid manufacturing footprints that reduce tariff exposure and logistical vulnerability.

Leaders must also prioritize regulatory engagement early and continuously, leveraging scientific advice and adaptive regulatory pathways to de-risk pivotal development steps and to clarify post-approval evidence commitments. Strategic partnerships merit active pursuit: form alliances with contract manufacturers, clinical networks, and technology providers to accelerate capacity build-out while preserving capital efficiency. Additionally, embed health economics and outcomes research into development plans to demonstrate value to payers and health systems; early modeling and real-world data capture will inform pricing and reimbursement strategies. Finally, cultivate operational excellence through investment in automation, digital tracking of chain-of-identity, and workforce training programs that reduce variability and accelerate time-to-patient across both autologous and allogenic programs.

Research methodology and evidence synthesis explaining data sources expert consultation methods analytical frameworks and validation processes used to build the analysis

The research methodology combines a structured evidence synthesis with primary qualitative engagement to deliver a robust, validated analysis. The approach began with a comprehensive review of publicly available scientific literature, regulatory guidance documents, clinical trial registries, and patent landscapes to develop a foundational understanding of platform technologies and clinical trajectories. This secondary research established key thematic hypotheses that were then tested through targeted expert consultations, including interviews with developers, manufacturing executives, clinical investigators, and regulatory specialists to obtain operational context and forward-looking perspectives.

Analytical frameworks employed include supply-chain mapping to identify chokepoints, segmentation analysis to align program strategy with clinical use cases, and scenario planning to assess policy and trade impacts. Findings were cross-checked through triangulation of evidence sources and validated in workshops with subject-matter experts to ensure practical relevance and to refine recommendations. Throughout, the process emphasized transparency of assumptions, traceability of evidence, and an iterative validation loop that incorporated stakeholder feedback to improve accuracy and applicability of the insights.

Concluding synthesis highlighting strategic imperatives persistent challenges and pragmatic pathways for stakeholders to maximize clinical and commercial impact in cell therapy

The conclusion synthesizes the analysis into a concise set of strategic imperatives for stakeholders across the cell therapy ecosystem. Scientific momentum continues to expand the range of viable therapeutic constructs, yet commercial success increasingly depends on operational excellence across manufacturing, supply chain, and payer engagement. Organizations that couple scientific differentiation with reproducible, scalable processes and early value demonstration will be better positioned to navigate regulatory expectations and secure durable market access. Persistent challenges-such as logistics for autologous therapies, manufacturing variability, and regional regulatory fragmentation-require coordinated response strategies that blend public-private collaboration with targeted investments.

Looking ahead, the ecosystem will reward adaptive organizations that embrace modular production models, invest in digital infrastructure for chain-of-identity and outcomes capture, and proactively engage payers to design evidence packages that reflect real-world performance. By integrating these strategic priorities with disciplined execution, stakeholders can accelerate patient access while managing the operational complexities inherent to advanced cell-based therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid emergence of allogeneic off-the-shelf CAR-T therapies with standardized dosing and reduced manufacturing timelines
  • 5.2. Integration of automated closed-loop bioreactor systems for scalable cell therapy production and quality control
  • 5.3. Application of CRISPR gene editing to engineer next generation universal donor T cells with enhanced tumor specificity
  • 5.4. Implementation of decentralized point-of-care manufacturing to streamline autologous cell therapy delivery to remote treatment centers
  • 5.5. Adoption of artificial intelligence-driven analytics for real-time potency assessment and release criteria optimization in cell therapies
  • 5.6. Expansion of cell therapy indications into solid tumor treatments through tumor microenvironment modulation strategies
  • 5.7. Development of combination regimens combining cell therapies with immune checkpoint inhibitors to improve durable response rates
  • 5.8. Establishment of global regulatory harmonization frameworks to accelerate clinical adoption and market authorization of cell treatments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Market, by Type

  • 8.1. Non-stem Cells
    • 8.1.1. CAR-T Cells
    • 8.1.2. Dendritic Cells
    • 8.1.3. NK Cells
  • 8.2. Stem Cells
    • 8.2.1. Embryonic Stem Cells
    • 8.2.2. Hematopoietic Stem Cell
    • 8.2.3. Mesenchymal Stem Cell

9. Cell Therapy Market, by Therapy Type

  • 9.1. Allogenic
  • 9.2. Autologous

10. Cell Therapy Market, by Mode of Administration

  • 10.1. Intramuscular
  • 10.2. Intratumoral
  • 10.3. Intravenous

11. Cell Therapy Market, by Application

  • 11.1. Autoimmune Disorders
    • 11.1.1. Multiple Sclerosis
    • 11.1.2. Rheumatoid Arthritis
  • 11.2. Cancer Treatment
    • 11.2.1. Hematologic Malignancies
    • 11.2.2. Solid Tumors
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
    • 11.3.2. Viral Infections
  • 11.4. Regenerative Medicine

12. Cell Therapy Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Clinics
  • 12.3. Commercial Laboratories
  • 12.4. Hospitals

13. Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Anterogen Co., Ltd.
    • 16.3.2. Astellas Pharma Inc.
    • 16.3.3. Athersys, Inc.
    • 16.3.4. BioNTech SE
    • 16.3.5. Bristol-Myers Squibb Company
    • 16.3.6. Castle Creek Biosciences, Inc.
    • 16.3.7. Catalent, Inc.
    • 16.3.8. FUJIFILM Holdings Corporation
    • 16.3.9. Gilead Sciences, Inc.
    • 16.3.10. JCR Pharmaceuticals Co., Ltd.
    • 16.3.11. Kolon TissueGene, Inc.
    • 16.3.12. Lonza Group Ltd.
    • 16.3.13. Medipost Co., Ltd.
    • 16.3.14. Mesoblast Ltd.
    • 16.3.15. Novartis AG
    • 16.3.16. NuVasive, Inc.
    • 16.3.17. Pfizer Inc.
    • 16.3.18. Sartorius AG
    • 16.3.19. Stemedica Cell Technologies, Inc.
    • 16.3.20. Stempeutics Research Pvt. Ltd.
    • 16.3.21. Takeda Pharmaceutical Company Limited
    • 16.3.22. TegoScience
    • 16.3.23. Thermo Fisher Scientific, Inc.
    • 16.3.24. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 335. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 336. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 337. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 338. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 339. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 340. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 341. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)